Immuno-Oncology: A Renaissance in the Treatment of NSCLC

Sunday, 9 October 2016
13:00 – 14:30

Bella Center Copenhagen
Athens Auditorium
Copenhagen, Denmark

Chair: Frances Shepherd (Canada)

Educational Objectives

- Establish a rationale for checkpoint inhibitors as a treatment option for lung cancer based on the mechanism of disease
- Educate on the immune-related adverse events associated with treatment of immunotherapies in lung cancer
- Educate on the role tumor expression can play in determining appropriate treatment options

AGENDA

13:00 – 13:05 Welcome and Introduction
Frances Shepherd

13:05 – 13:20 Anti-PD-1 Experience in NSCLC
Frances Shepherd

13:20 – 13:30 The Value of PD-L1 Expression in NSCLC
Reinhard Büttner

13:30 – 14:00 Patient Management
- Example Case
Naiyer Rizvi

13:45 – 14:00 NSCLC Landscape: Future Directions
Andrea Ardizzoni

14:00 – 14:30 Panel Discussion
Faculty

14:30 Closing Remarks
Frances Shepherd

Presentations and patient cases were independently prepared by the speakers with no influence of MSD.